March 2018

Feature

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Chadi Nabhan, MD, MBA, FACP

Yolaine Jeune-Smith, PhD

Amy Valley, PharmD

Bruce A Feinberg, DO

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways

Column

PATIENT PERSPECTIVE

The Time Has Come to Involve Patients in Clinical Pathways

03/15/2018

Alan Balch, PhD—Column Editor

Patients are not often given a voice in the development and implementation of clinical pathways, the main focus of which have been to provide treatment options and guidance primarily based on clinical medical...

...

03/15/2018

Journal of Clinical Pathways

Pharma Insights

What Changes When Medicine Goes Digital?

03/15/2018

Amanda Lever, BSc

Auralyn MacKenzie, BSc

Larry Blandford, PharmD—Column Editor

Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....

Health...

03/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Targeting the Quadruple Aim Through Clinical Pathways

03/15/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

All health care professionals recognize the Triple Aim, which is focused on outcomes, costs, and patient experiences. However, a fourth aim was added, which focuses on an essential, yet often forgotten, contribution...

All...

03/15/2018

Journal of Clinical Pathways

Editor's Page

Preserving Patient and Provider Voice in Clinical Pathway Development and Use

03/15/2018

Winston Wong, PharmD, Editor-in-Chief

In our increasingly digital world, providers’ and patients’ voices and individual needs must be prioritized. When it comes to treating others or being treated for incredibly complex illnesses, the health and...

In our...

03/15/2018

Journal of Clinical Pathways

Department

A Heart Failure Clinical Pathway to Reduce Hospital Readmissions

03/15/2018

JCP Editors

Heart failure (HF) is the primary diagnosis in over 1 million hospitalizations annually,1 and patients who are hospitalized for HF are at high risk for all-cause hospital readmission, with a 1-month readmission rate...

Heart...

03/15/2018

Journal of Clinical Pathways

News

Conference Coverage

American Society of Clinical Oncology Cancer Survivorship Symposium

03/15/2018

JCP Editors

The American Society of Clinical Oncology (ASCO) featured its Cancer Survivorship Symposium in Orlando, Florida from February 16-17, 2018. The meeting provided information about survivorship issues that both...

The...

03/15/2018

Journal of Clinical Pathways

Conference Coverage

American Society of Clinical Oncology Genitourinary Cancers Symposium

03/15/2018

JCP Editors

The 2018 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium provides a forum for physicians and other members of the oncology care and research community who diagnose, treat, and...

The...

03/15/2018

Journal of Clinical Pathways

Department

Research in Review

Reviewing the Latest Research on Value-Based Care, Clinical Pathways, and Precision Medicine

03/15/2018

JCP Editors

ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for...

ASCO...

03/15/2018

Journal of Clinical Pathways

Erratum

Erratum: Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs

03/15/2018

Ladan Golestaneh, MD, MS

Paula J Alvarez, RPh, MPH, MBA

Nancy L Reaven, MA

Susan E Funk, MBA, FACHE

Karen J McGaughey, PhD

Alain Romero, PharmD, PhD

Macaulay Onuigbo, MD, MSc, MBA

The article, “Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs,” appearing in the November 2017 issue of Journal of Clinical Pathways, was updated for minor editorial additions and...

The...

03/15/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

March 2018

Feature

Column

News

Department

Current Issue

Special Reports

Subscribe

Volume 4

Specialties

Events

Year Round Education

HMP Global Products